Taysha raises $150M PIPE, shares single patient data on Rett syndrome gene therapy
Taysha Gene Therapies announced it raised $150 million from a stock sale to investors as it unveiled data from a single Rett syndrome patient who received its gene therapy.
The data are still early and very limited, but in a single adult female patient who received its Rett syndrome gene therapy, Taysha said there have been no safety issues at six weeks. On one primary endpoint, Taysha said the clinician reported a score of two on a seven-point improvement scale, meaning the patient was “much improved” at four weeks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.